



OFFICIAL WEBSITE NOTICE

Posting Date: August 10, 2023

**RECOMMENDATIONS OF DRUG USE REVIEW / PHARMACY AND
THERAPEUTICS COMMITTEE**

The Oregon Drug Use Review / Pharmacy and Therapeutics Committee met virtually on Thursday, August 3, 2023. The Committee considered in order of priority: the safety and efficacy of the drugs being considered; the ability of Oregonians to access effective prescription drugs that are appropriate for their clinical conditions; and substantial differences in costs of drugs within the same therapeutic class. Based upon the clinical information presented by staffⁱ and all public comment offered,ⁱⁱ while considering the impact on people, populations and communities who have been most impacted by historic and contemporary injustices and health inequities including but not limited to Oregon Tribal Nations, American Indian or Alaska Native persons, Hispanic, Latino, Latina, or Latinx persons, Black or African American persons, Asian or Asian American persons, Pacific Islander or Native Hawaiian persons, people with disabilities, people with limited English proficiency, and immigrants and refugees, the Committee makes the following recommendations for Drug Use Review, the Oregon Practitioner-Managed Prescription Drug Plan (PMPDP), or for any other preferred drug list established by the Oregon Health Authority:

Drug Use Review (DUR) Recommendations:

Oncology Policy Updates

The Committee recommended adding the following new FDA-approved antineoplastic agents to Table 1 in the Oncology Agents prior authorization (PA) criteria: Epkinly™ (epcoritamab-bysp); and Columvi™ (glofitamab-gxbm).

Calcitonin Gene-Related Peptide (CGRP) Inhibitors

After comparative cost consideration in the executive session, the Committee recommended making Ubrelvy™ preferred on the PMPDP contingent on acceptance of a supplemental rebate offer that is similar in population scope to current contract.

DRUG	CHANGE
Ubrelvy™ (ubrogepant)	Make preferred on the PMPDP

Sublingual Buprenorphine Quantity Limit Policy Evaluation

The Committee recommended increasing the maximum dose limit to 32 mg daily for sublingual buprenorphine formulations and to update the current PA criteria to permit use of higher doses for opioid use disorder with medical justification. The Committee also approved implementing a days' supply limit for all sublingual buprenorphine formulations to support quantity limits.

Practitioner-Managed Prescription Drug Plan (PMPDP) Recommendations:

Daybue™ (trofinetide) New Drug Evaluation (NDE)

The Committee recommended maintaining trofinetide as non-preferred on the PMPDP and implementing the proposed PA criteria as amended to remove assessment for type of Rett syndrome and to refer requests to the medical director when Rett syndrome has not been genetically confirmed.

Benign Prostatic Hyperplasia (BPH) Class Update

The Committee recommended making no changes to the PMPDP based on review of recently published clinical evidence and to update the PA criteria as proposed – including removal of the renewal criteria. After comparative cost consideration in the executive session, the Committee recommended making no changes to the PMPDP.

Vowst™ (oral fecal microbiota spores, live-brpk) NDE

The Committee recommended maintaining oral fecal microbiota capsules as non-preferred on the PMPDP and applying the “Prevention of C. difficile Recurrence” clinical PA criteria as amended to add step therapy that requires fecal microbiota transplant before use of bezlotoxumab. After comparative cost consideration in the executive session, the Committee recommended making no changes to the PMPDP.

Non-injectable Allergen Immunotherapy Class Review

The Committee recommended adding Grastek®, Oralair®, Ragwitek®, and Odactra® sublingual tablets to the “Immunotherapy Desensitization, non-injectable” PMPDP class and designate non-preferred. The Committee recommended implementing the proposed “Sublingual Immunotherapy Tablets” PA criteria to allow for coverage under the Early and Periodic Screening, Diagnostic and Treatment (EPSDT) Program

but amended to only permit the use of Odactra[®] (dust mite sublingual immunotherapy) in people with allergic rhinitis complicated by comorbid asthma. After comparative cost consideration in the executive session, the Committee recommended making all sublingual tablets non-preferred on the PMPDP.

DRUG	CHANGE
Grastek [®] sublingual tablets	Make non-preferred on the PMPDP
Oralair [®] sublingual tablets	Make non-preferred on the PMPDP
Ragwitek [®] sublingual tablets	Make non-preferred on the PMPDP
Odactra [®] sublingual tablets	Make non-preferred on the PMPDP

Endocrine Therapies Class & Prior Authorization Updates


The Committee recommended making no changes to the PMPDP based on review of recently published clinical evidence. The Committee supported revising the GnRH agonists, estrogen, and testosterone PA criteria to comport with recently enacted state legislation, HB 2002, as well as to include an EPSDT assessment. After comparative cost consideration in the executive session, the Committee recommended making Lupron Depot-PED[®] kit formulations (1-month, 3-month, and 6-month) preferred on the PMPDP.

DRUG	CHANGE
Lupron (leuprolide) Depot-PED [®] Kits	Make preferred on the PMPDP

The Committee has made these recommendations to the Oregon Health Authority for approval by the Director of the Oregon Health Authority.

APPROVAL BY THE DIRECTOR OF THE OREGON HEALTH AUTHORITY

All other recommendations of the Drug Use Review / Pharmacy and Therapeutics Committee are approved. Recommendations with respect to the inclusion of a drug on the PMPDP will be put into place no earlier than 7 days from the date this notice is posted on the website.



 Dave Baden
 Interim Director

8/10/2023

 Approval date

A request for reconsideration of this decision to adopt the recommendations of the Drug Use Review / Pharmacy and Therapeutics Committee must be filed with and received by the Director no later than 7 calendar days from the date of this notice. ORS 414.361(6)(b).

ⁱ https://www.orpdl.org/durm/meetings/meetingdocs/2023_08_03/finals/2023_08_03_PnT_Complete.pdf

ⁱⁱ https://www.orpdl.org/durm/meetings/meetingdocs/2023_08_03/finals/2023_08_03_WrittenTestimony.pdf